MX358991B - Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. - Google Patents
Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.Info
- Publication number
- MX358991B MX358991B MX2014013676A MX2014013676A MX358991B MX 358991 B MX358991 B MX 358991B MX 2014013676 A MX2014013676 A MX 2014013676A MX 2014013676 A MX2014013676 A MX 2014013676A MX 358991 B MX358991 B MX 358991B
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- binding molecules
- following stroke
- promote neurogenesis
- neurogenesis following
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646119P | 2012-05-11 | 2012-05-11 | |
| US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| PCT/US2013/040661 WO2013170221A1 (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013676A MX2014013676A (es) | 2015-02-05 |
| MX358991B true MX358991B (es) | 2018-08-31 |
Family
ID=49548777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013676A MX358991B (es) | 2012-05-11 | 2013-05-10 | Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10494440B2 (https=) |
| EP (1) | EP2846831B1 (https=) |
| JP (1) | JP6218810B2 (https=) |
| KR (1) | KR102105436B1 (https=) |
| CN (2) | CN110064054A (https=) |
| AU (1) | AU2013259192B2 (https=) |
| BR (1) | BR112014028160B1 (https=) |
| CA (1) | CA2872928C (https=) |
| DK (1) | DK2846831T3 (https=) |
| EA (1) | EA030796B1 (https=) |
| ES (1) | ES2882881T3 (https=) |
| IL (1) | IL235603B (https=) |
| MX (1) | MX358991B (https=) |
| NZ (1) | NZ630864A (https=) |
| PT (1) | PT2846831T (https=) |
| SG (1) | SG11201407416XA (https=) |
| WO (1) | WO2013170221A1 (https=) |
| ZA (1) | ZA201501674B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| CN110325213A (zh) * | 2017-02-22 | 2019-10-11 | 瓦西尼斯公司 | 神经退行性或神经炎性疾病中胶质细胞活化的早期检测 |
| WO2018204895A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| WO2024182357A1 (en) * | 2023-02-28 | 2024-09-06 | Brandeis University | Compositions and methods for the chronic treatment of epilepsy and epileptogenesis |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| CA2554735A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| EP1773885B1 (en) | 2004-08-05 | 2010-04-21 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| AU2006235271B2 (en) | 2005-04-07 | 2011-05-19 | Novartis Vaccines And Diagnostics Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| CA2755198A1 (en) * | 2009-03-13 | 2010-09-16 | Mark L. Tykocinski | Ox40/trail fusion proteins |
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| NZ604464A (en) | 2010-06-14 | 2014-03-28 | Vaccinex Inc | Anti-vegf antibodies and uses thereof |
| KR102003571B1 (ko) | 2011-05-13 | 2019-07-24 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 골형성 촉진제 |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN110325213A (zh) * | 2017-02-22 | 2019-10-11 | 瓦西尼斯公司 | 神经退行性或神经炎性疾病中胶质细胞活化的早期检测 |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en not_active Ceased
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/en active Active
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active Active
- 2013-05-10 CA CA2872928A patent/CA2872928C/en active Active
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/en not_active Ceased
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en not_active IP Right Cessation
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt not_active IP Right Cessation
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL235603B (en) | 2020-01-30 |
| EP2846831A1 (en) | 2015-03-18 |
| ES2882881T3 (es) | 2021-12-03 |
| MX2014013676A (es) | 2015-02-05 |
| IL235603A0 (en) | 2015-01-29 |
| EA030796B1 (ru) | 2018-09-28 |
| EA201492067A1 (ru) | 2015-05-29 |
| DK2846831T3 (en) | 2021-10-11 |
| WO2013170221A1 (en) | 2013-11-14 |
| NZ630864A (en) | 2017-03-31 |
| JP6218810B2 (ja) | 2017-10-25 |
| CN110064054A (zh) | 2019-07-30 |
| SG11201407416XA (en) | 2015-03-30 |
| EP2846831B1 (en) | 2021-07-07 |
| KR102105436B1 (ko) | 2020-04-29 |
| CA2872928C (en) | 2021-02-16 |
| JP2015517502A (ja) | 2015-06-22 |
| US10494440B2 (en) | 2019-12-03 |
| AU2013259192B2 (en) | 2018-02-22 |
| BR112014028160B1 (pt) | 2021-01-12 |
| CN104619341A (zh) | 2015-05-13 |
| ZA201501674B (en) | 2021-06-30 |
| KR20150018555A (ko) | 2015-02-23 |
| US20130302320A1 (en) | 2013-11-14 |
| CA2872928A1 (en) | 2013-11-14 |
| EP2846831A4 (en) | 2015-11-18 |
| PT2846831T (pt) | 2021-08-19 |
| AU2013259192A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014013676A (es) | Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| MX2014004457A (es) | Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| MX2022004300A (es) | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. | |
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| EA201391585A1 (ru) | Терапевтические нуклеазные композиции и способы | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| PH12013501636A1 (en) | Treatment of osteoarthritis and pain | |
| EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
| PH12013501490A1 (en) | Methods for diagnosing and treating eye-length related disorders | |
| MX350378B (es) | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
| MX2018008882A (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| EA201500370A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ | |
| WO2012138708A8 (en) | Mhc engagement and clip modulation for the treatment of disease | |
| SG10201908587PA (en) | Treatment regimens | |
| WO2012136351A8 (en) | Tapentadol for treating pain associated with trigeminal neuralgia | |
| WO2012004416A3 (en) | Treatment of a disease associated with retinal degenerative disorder | |
| TN2014000207A1 (en) | Anti il-36r antibodies | |
| BR112013028891A2 (pt) | molécula para tratar um distúrbio inflamatório | |
| UA97054C2 (ru) | Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |